Santen Pharmaceutical Forecast, price target & analysts
Santen Pharmaceutical Target price 2025 - Analyst rating & recommendation
Santen Pharmaceutical Classifications & Recommendation:
Santen Pharmaceutical Price Target
| Target Price | JPY2,122.22 |
| Price | JPY1,689.50 |
| Potential |
25.61%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Santen Pharmaceutical 2026 .
The average Santen Pharmaceutical target price is JPY2,122.22.
This is
25.61%
register free of charge
JPY2,600.00
53.89%
register free of charge
JPY1,700.00
0.62%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Santen Pharmaceutical to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Santen Pharmaceutical stock has an average upside potential 2026 of
25.61%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion JPY | 300.00 | 294.10 |
| 0.65% | 1.97% | |
| EBITDA Margin | 18.56% | 21.50% |
| 9.82% | 15.82% | |
| Net Margin | 12.08% | 12.01% |
| 36.98% | 0.60% |
10 Analysts have issued a sales forecast Santen Pharmaceutical 2026 . The average Santen Pharmaceutical sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Santen Pharmaceutical EBITDA forecast 2026. The average Santen Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Santen Pharmaceutical Analysts have issued a net profit forecast 2026. The average Santen Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share JPY | 103.97 | 103.45 |
| 43.72% | 0.50% | |
| P/E | 16.33 | |
| EV/Sales | 1.85 |
6 Analysts have issued a Santen Pharmaceutical forecast for earnings per share. The average Santen Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Santen Pharmaceutical...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
